Damien Kee

5PUBLICATIONS
61CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 13, 2026
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

|Apr 24, 2026
Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial.

|Jun 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.

Caroline Robert, Matteo S Carlino, Catriona McNeil

|Jul 29, 2021
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley

|Jun 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.

Oliver Klein, Damien Kee, Ben Markman

Pageof 1

Frequent Collaborators

2 joint publications

Michael Michael

2 joint publications

Clare Scott

2 joint publications

Jane Y So

2 joint publications

Jodie Palmer